Association between the expression levels of TAZ, AXL and CTGF and clinicopathological parameters in patients with colon cancer Corrigendum in /10.3892/ol.2016.4464

Zhang,Shu‑Dong; Mccrudden,Cian M.; Yuen,Hiu‑Fung; Leung,Ka Lai; Hong,Wan‑Jin; Kwok,Hang Fai

doi:10.3892/ol.2015.3999

February-2016 Volume 11 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

February-2016 Volume 11 Issue 2

Full Size Image

Article

Association between the expression levels of TAZ, AXL and CTGF and clinicopathological parameters in patients with colon cancer

Corrigendum in: /10.3892/ol.2016.4464

Authors:
- Shu‑Dong Zhang
- Cian M. Mccrudden
- Hiu‑Fung Yuen
- Ka Lai Leung
- Wan‑Jin Hong
- Hang Fai Kwok
View Affiliations / Copyright

Affiliations: Faculty of Health Sciences, University of Macau, Macau, SAR, P.R. China, Center for Cancer Research and Cell Biology, School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Proteos, Singapore 138673, Republic of Singapore
Pages: 1223-1229
|
Published online on: December 3, 2015

https://doi.org/10.3892/ol.2015.3999
Expand metrics +

Abstract

Colon cancer accounts for a large proportion of all the cancer‑associated morbidities worldwide. Genetic analysis and stratification of patients based on survival may identify genetic signatures potentially useful for prognostic or treatment planning purposes. Previous studies have reported that the messenger (m)RNA expression levels of tafazzin (TAZ), AXL receptor tyrosine kinase (AXL) and connective tissue growth factor (CTGF) were able to predict the survival of patients with colon cancer in two independent colon cancer datasets. However, limited clinicopathological data were available from these two datasets. By contrast, a large colon cancer dataset comprising 566 patients has been recently published in the Gene Expression Omnibus database, which contains data regarding tumor stage and location, and genetic status of mismatch repair (MMR), Kirsten rat sarcoma viral oncogene homolog (KRAS), B‑Raf proto‑oncogene serine/threonine kinase (BRAF) and tumor protein p53 (TP53). In the present study, the mRNA expression levels of TAZ, AXL and CTGF were evaluated, and the TAZ‑AXL‑CTGF signature was correlated with the available pathological parameters and survival data. Overexpression of TAZ, AXL and CTGF was observed to be associated with severe pathological stage, deficiency in MMR, colon cancer subtype C4 and mutations in the BRAF gene. In addition, overexpression of TAZ‑AXL‑CTGF was associated with short overall survival in patients with mutations in the TP53 gene, colon cancer subtype C6, proficient MMR and wild‑type status of the KRAS and BRAF genes. Furthermore, the prognostic value of TAZ‑AXL‑CTGF overexpression was observed to be independent of all the clinicopathological parameters and mutational statuses analyzed. The results of the present study confirm the previously reported findings, and suggest that the TAZ‑AXL‑CTGF mRNA signature is a potential prognostic indicator in colon cancer.

View Figures

View References

1	Winder T and Lenz HJ: Molecular predictive and prognostic markers in colon cancer. Cancer Treat Rev. 36:550–556. 2010. View Article : Google Scholar : PubMed/NCBI
2	Sridharan M, Hubbard JM and Grothey A: Colorectal cancer, How emerging molecular understanding affects treatment decisions. Oncology (Williston Park). 28:110–118. 2014.PubMed/NCBI
3	Stein A, Hiemer S and Schmoll HJ: Adjuvant therapy for early colon cancer, Current status. Drugs. 71:2257–2275. 2011. View Article : Google Scholar : PubMed/NCBI
4	Hong W and Guan KL: The YAP and TAZ transcription co-activators: Key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol. 23:785–793. 2012. View Article : Google Scholar : PubMed/NCBI
5	Yuen HF, McCrudden CM, Huang YH, Tham JM, Zhang X, Zeng Q, Zhang SD and Hong W: TAZ expression as a prognostic indicator in colorectal cancer. PLoS One. 8:e542112013. View Article : Google Scholar : PubMed/NCBI
6	Wang L, Shi S, Guo Z, Zhang X, Han S, Yang A, Wen W and Zhu Q: Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PLoS One. 8:e655392013. View Article : Google Scholar : PubMed/NCBI
7	Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D, Ayadi M, et al: Gene expression classification of colon cancer into molecular subtypes: Characterization, validation, and prognostic value. PLoS Med. 10:e10014532013. View Article : Google Scholar : PubMed/NCBI
8	di Pietro M, Bellver Sabates J, Menigatti M, Bannwart F, Schnider A, Russell A, Truninger K, Jiricny J and Marra G: Defective DNA mismatch repair determines a characteristic transcriptional profile in proximal colon cancers. Gastroenterology. 129:1047–1059. 2005. View Article : Google Scholar : PubMed/NCBI
9	Compton CC and Greene FL: The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin. 54:295–308. 2004. View Article : Google Scholar : PubMed/NCBI
10	Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, et al: Predictive and prognostic roles of BRAF mutation in stage III colon cancer: Results from intergroup trial CALGB 89803. Clin Cancer Res. 18:890–900. 2012. View Article : Google Scholar : PubMed/NCBI
11	Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, Kondo C, Mizota A, Utsunomiya S, Muro K and Yatabe Y: BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer. 104:856–862. 2011. View Article : Google Scholar : PubMed/NCBI
12	French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, Shepherd L, Windschitl HE and Thibodeau SN: Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res. 14:3408–3415. 2008. View Article : Google Scholar : PubMed/NCBI
13	Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, et al: DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 103:863–875. 2011. View Article : Google Scholar : PubMed/NCBI